INDICATIONS

Repatha® is indicated:

  • In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization... READ MORE
  • Encourage Patients to Sign Up for AMGEN® SupportPlus

    Reduce out-of-pocket costs for patients

    Empower patients with Amgen® Nurse Partners

    Resources designed to help increase access

    You can email your appropriate patients a direct link to enroll in the services provided by Amgen® SupportPlus

    We’re Right Here, Right When You Need Us

    Personalized support that you and your patients can count on across Amgen® therapies.

    Out-of-Pocket Cost Icon

    Financial Support Resources

    We know every patient has unique needs. And we’re here to provide financial support information and resources, regardless of their current financial situation or type of insurance they have.

    • Commercial Insurance

    • Government Insurance

    • Uninsured

    Repatha® Co-Pay Card

    The Repatha® Co-Pay Program may help eligible patients with private or commercial insurance lower their out-of-pocket costs.

    • Pay as little as $5* out-of-pocket
    • Can be applied to deductible, co-insurance, and co-payment*
    • No income eligibility requirement
    Encourage your patients with private or commercial insurance to check eligibility and enroll.

    *Eligibility criteria and program maximums apply. See below for full Terms and Conditions.

    Medicaid

    99%

    of prescriptions cost patients

    $10 or less1

    Medicare

    ~71%

    of prescriptions cost patients

    $49 or less1

    Learn how Amgen® SupportPlus can help your patients access their prescribed medication.

    Call Amgen® SupportPlus at

    1-844-REPATHA (1-844-737-2842),
    Monday – Friday 8:00am – 8:00pm ET to learn more.

    What if my patient doesn’t have private or commercial insurance?

    Amgen® SupportPlus can provide your patients with information about independent nonprofit foundations that may be able to help*

    *Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit’s criteria. Amgen has no control over the programs and provides information as a courtesy only.

    Learn how Amgen® SupportPlus can help your patients access their prescribed medication.

    Call Amgen® SupportPlus at

    1-844-REPATHA (1-844-737-2842),
    Monday – Friday 8:00am – 8:00pm ET to learn more.
    Amgen® Nurse Icon

    Amgen® Nurse Partners

    Dedicated Amgen Nurse Partners can offer supplemental support to help your patients on their journey.

    Amgen Nurse Partners can provide supplemental support, including:

    • Supplemental injection education and support
    • Guidance on resources that may help lower out-of-pocket medication costs
    • Assistance to help your patients stay on track with their medication
    • Answers to questions about Amgen SupportPlus

    Your patients can enroll in the Amgen Nurse Partner Program online at repatha.com or by calling 1-844-REPATHA (1-844-737-2842).

    Amgen Nurse Partners are only available to patients that are prescribed certain Amgen products. They are not part of your patient’s treatment team and do not provide medical advice, nursing, or case management services. Amgen Nurse Partners will not inject patients with Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

    Amgen® Access Specialist Icon

    Amgen® Access Specialists

    An Amgen Access Specialist can provide live or virtual coverage and access resources to support your patients.

    Contact your Amgen Access Specialist for live or virtual support, that includes:

    • Help with navigating prior authorization, appeals, and fulfillment processes
    • Educating on payer requirements and necessary documentation for individual patient support
    • Answers to general questions about Amgen SupportPlus programs and other available resources
    • Navigating the benefit verification process

    Your Amgen representative can connect you with an Access Specialist or call 1-844-REPATHA Monday – Friday 8:00am – 8:00pm ET

    Repatha® Co-Pay Card Terms and Conditions

    SUMMARY OF TERMS AND CONDITIONS

    It is important that every patient read and understand the full Repatha® Co-Pay Card Terms and Conditions. The following summary is not a substitute for reviewing the Terms and Conditions in their entirety.

    As further described below, in general:

    • The Repatha® Co-Pay Card is open to patients with commercial insurance, regardless of financial need. The program is not valid for patients whose Repatha® prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state healthcare program. It is not valid for cash-paying patients or where prohibited by law. (See ELIGIBILITY section below.)
    • With the Repatha® Co-Pay Card, a commercially insured patient who meets eligibility criteria may pay as little as a $5 Co-Pay per month for their Repatha® monthly out-of-pocket costs. Monthly out-of-pocket costs include co-payment, co-insurance, and deductible out-of-pocket costs. Amgen will pay the remaining eligible out-of-pocket costs on behalf of the patient up to a Maximum Monthly Benefit, a Maximum Annual Program Benefit and/or the Patient Total Program Benefit. Patients are responsible for all amounts that exceed these limits. (See PROGRAM DETAILS section below.)
    • Offer is subject to change or discontinuation without notice.
    • The Repatha® Co-Pay Card provides support up to the Maximum Monthly Benefit, the Maximum Annual Program Benefit and/or Patient Total Program Benefit. If a patient’s commercial insurance plan imposes different or additional requirements on patients who receive Repatha® Co-Pay Card benefits, Amgen has the right to modify or eliminate those benefits. Whether you are eligible to receive the Maximum Monthly Benefit, Maximum Program Benefit or Patient Total Program Benefit is determined by the type of plan coverage you have. Please ask your Amgen SupportPlus Representative to help you understand eligibility for the Repatha® Co-Pay Card, and whether your particular insurance coverage is likely to result in your reaching the Maximum Monthly Benefit, the Maximum Annual Program Benefit, or your Patient Total Program Benefit, by calling 1-844-REPATHA (1-844-737-2842). (See PROGRAM BENEFITS section below.)
    • I. ELIGIBILITY

      Eligibility Criteria: Subject to program limitations and terms and conditions, the Repatha® Co-Pay Card is open to patients who have a Repatha® prescription and who have commercial or private insurance, including plans available through state and federal healthcare exchanges. This program helps eligible patients cover out-of-pocket costs related to Repatha®, up to program limits. There is no income requirement to participate in this program.

      This offer is not valid for patients whose Repatha® prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. It is not valid for cash-paying patients or where prohibited by law. A patient is considered cash-paying where the patient has no insurance coverage for Repatha® or where the patient has commercial or private insurance but Amgen in its sole discretion determines the patient is effectively uninsured because such coverage does not provide a material level of financial assistance for the cost of a Repatha® prescription. This offer is only valid in the United States, Puerto Rico, and the US territories.

      II. PROGRAM BENEFITS

      The Repatha® Co-Pay Card helps provide out-of-pocket support to eligible patients for their Repatha® prescription up to program limits. See PROGRAM DETAILS for full description.

      The Repatha® Co-Pay Card offer does not cover out-of-pocket costs for any patient whose selected coverage option under their commercial insurance plan does not apply Repatha® Co-Pay Card payments to satisfy the patient’s co-payment, deductible, or co-insurance for Repatha®. Patients with these plan limitations are not eligible for the Repatha® Co-Pay Card but may be eligible for other needs-based assistance provided by Amgen. These programs are often referred to as accumulator adjustment programs. If you believe your commercial insurance plan may have such limitations, please contact Amgen SupportPlus at 1-844-REPATHA (1-844-737-2842).

      The Repatha® Co-Pay Card may modify the benefit amount, unilaterally determined by Amgen in its sole discretion, to satisfy the out-of-pocket cost-sharing requirement for any patient whose plan or plan agent (including, but not limited to, a Pharmacy Benefit Manager (PBM) requires enrollment in the Repatha® Co-Pay Card as a condition of the plan or PBM waiving some or all of an otherwise applicable patient out-of-pocket cost-sharing amount. These programs are often referred to as co-pay maximizer programs. If you believe your commercial insurance plan may have such limitations, please contact Amgen SupportPlus at 1-844-REPATHA (1-844-737-2842). Health plans and Pharmacy Benefit Managers are prohibited from enrolling or assisting in the enrollment of patients in the Repatha® Co-Pay Card. The patient, or his/her legal representative, must personally enroll in the Repatha® Co-Pay Card in order to be eligible for program benefits.

      If at any time a patient begins receiving prescription drug coverage under any federal, state or government healthcare program (including but not limited to Medicare, Medicaid, TRICARE, Department of Defense, or Veteran Affairs programs), the patient will no longer be able to use this card and they must contact Amgen SupportPlus at 1-844-REPATHA (1-844-737-2842) to stop their participation in this program.

      Patients may not seek reimbursement for the value received from the Repatha® Co-Pay Card from any third-party payers, including a flexible spending account or healthcare savings account. Participating in this program means that you are ensuring you comply with any required disclosure regarding your participation in the Repatha® Co-Pay Card of your insurance carrier or Pharmacy Benefit Manager. Restrictions may apply. Offer is subject to change or discontinuation without notice. This is not health insurance.

      III. PROGRAM DETAILS

      With the Repatha® Co-Pay Card, a commercially insured patient who meets eligibility criteria may pay as little as a $5 Co-Pay per month for their Repatha® monthly out-of-pocket costs.

    • For all eligible patients, the Repatha® Co-Pay Card offers:
      • A program benefit that covers the patient’s eligible out-of-pocket prescription costs for Repatha® (co-pay, deductible, or co-insurance) on behalf of the patient, up to a Maximum Monthly Benefit and/or a Maximum Annual Program Benefit.
      • Repatha® patients may pay $5 out of pocket at the first fill and at every refill, and Amgen will pay on behalf of the patient the remaining eligible out-of-pocket prescription costs (up to the Patient Total Program Benefit described below; Repatha® patients are responsible for all amounts that exceed this limit).
    • Maximum Monthly Benefit, Maximum Annual Program Benefit, and/or Patient Total Program Benefit and Benefits May Change, End, or Vary without notice.
    • The Maximum Annual Program Benefit must be applied to the Repatha® patient’s out-of-pocket costs (co-pay, deductible, or co-insurance).
    • The Patient Total Program Benefit amounts are unilaterally determined by Amgen in its sole discretion and will not exceed the Maximum Monthly Benefit or Maximum Annual Program Benefit. The Patient Total Program Benefit may be less than the Maximum Monthly Benefit or Maximum Annual Program Benefit, depending on the terms of a patient’s prescription drug plan, and may vary among individual patients covered by different plans, based on factors determined solely by Amgen, to ensure all programs funds are used for the benefit of the patient. Each patient is responsible for costs above the Patient Total Program Benefit amounts. Please ask your Amgen SupportPlus Representative to help you understand whether your particular insurance coverage is likely to result in your reaching the Maximum Monthly Benefit, Maximum Annual Program Benefit or your Patient Total Program Benefit amount by calling 1-844-REPATHA (1-844-737-2842) and follow the prompts.
    • Participating patients are solely responsible for updating Amgen with changes to their prescription health insurance including, but not limited to, initiation of insurance provided by the government, the addition of any coverage terms that do not apply Repatha® Co-Pay Card benefits to reduce a patient’s out-of-pocket costs, such as accumulator adjustment benefit design or a co-pay maximization program. Participating patients are responsible for providing Amgen with accurate information necessary to determine program eligibility. By accepting payments from Amgen made on behalf of participating patients, participating PBMs and Plans likewise are responsible for providing Amgen with accurate information regarding patient eligibility.
    • Patients may use the card every time they fill their Repatha® prescription. Benefits reset each calendar year. Re-enrollment in the program is required at regular intervals. Patients may continue in the program as long as the patient re-enrolls as required by Amgen and continues to meet all of the program’s eligibility requirements during participation in the program. Patients can enroll/re-enroll by calling 1-844-REPATHA (1-844-737-2842) or by going to Repatha.com/copay.

    Reference: 1. Data on file, Amgen; 2021.

    References: 1. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139-e596. doi:10.1161/cir.0000000000000757 2. Salah HM, Minhas AMK, Khan MS, et al. Causes of hospitalization in the USA between 2005 and 2018. Eur Heart J Open. 2021;1(1):oeab001. doi:10.l093/ehjopen/oeab001 3. Punekar RS, Fox KM, Richhariya A, et al. Burden of first and recurrent cardiovascular events among patients with hyperlipidemia. Clin Cardiol. 2015;38(8):483-491. doi:10.1002/clc.22428 4. McKinley EC, Bittner VA, Brown TM, et al. The projected impact of population-wide achievement of LDL cholesterol <70 mg/dL on the number of recurrent events among US adults with ASCVD. Cardiovasc Drugs Ther. 2023;37(1):107-116. doi:10.1007/s10557-021-07268-x 5. Levintow SN, Reading SR, Noshad S, et al. Lipid testing trends before and after hospitalization for myocardial infarction among adults in the United States, 2008-2019. Clin Epidemiol. 2022;14:737-748. doi:10.2147/clep.s361258 6. Chen C-C, Rane PB, Hines DM, Patel J, Harrison DJ, Wade RL. Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients. Ther Clin Risk Manag. 2018;14:2425-2435. doi:10.2147/tcrm.s180783 7. Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941-950. doi:10.1016/S2213-8587(17)30313-3 8. Muntner P, Orroth KK, Mues KE, et al. Evaluating a simple approach to identify adults meeting the 2018 AHA/ACC cholesterol guideline definition of very high risk for atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther. 2022;36(3):475-481. doi:10.1007/s10557-021-07167-1 9. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350. doi:10.1016/j.jacc.2018.11.003

    Important Safety Information

    Contraindications: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

    Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

    Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

    From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

    Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

    Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

    Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

    Indications

    Repatha® is indicated:

    • In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization.
    • As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C.

    Please see full Prescribing Information.